Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Human anti-cancer drugs could help Tasmanian devils
Tasmanian devils are considered endangered as a result of devil facial tumour 1.
RTKs have ‘an important role’ in sustaining transmissible cancers

Key drugs used to treat cancer in humans may also be useful in the fight against transmissible cancers in Tasmanian devils.

This is according to a new study by the University of Cambridge, which found that certain drugs used in humans were able to efficiently stop the growth of devil cancer cells in the lab.

The research, published in the journal Cancer Cell, shows that molecules known as receptor tyrosine kinases (RTKs) have an important role to play in sustaining the growth and survival of transmissible cancers in devils. Drugs targeting RTKs have already been developed for human cancers.

Tasmanian devils are considered endangered as a result of devil facial tumour 1 (DFT1), which is passed between animals through biting and causes disfiguring facial tumours. Usually fatal, DFT1 has spread throughout Tasmania since it was first seen in 1996, causing significant declines in devil populations.

Routine diagnostic screening in 2014 uncovered a second transmissible cancer in the species. With the naked eye, facial tumours caused by devil facial tumour 2 (DFT2) cannot be distinguished from those caused by DFT1, but analysis has shown they differ at a biological level.

Cambridge researchers found striking similarities between the two cancer types; in terms of genetics, tissues of origin, the way in which the cancer cells mutate and possible drug targets.

First author Dr Elizabeth Murchison said: “The story of Tasmanian devils in recent years has been a very concerning one. This study gives us optimism that anti-cancer drugs that are already in use in humans may offer a chance to assist with conservation efforts for this iconic animal.”

Become a member or log in to add this story to your CPD history

Vets to run marathon for World Animal Protection

News Story 1
 Two recently graduated veterinary surgeons will be running the London Marathon in April to raise money for the charity World Animal Protection.

Alex Bartlett and Maeve O'Neill plan to run the race together if they are given the same start times.

Dr O'Neill said: "You're always limited in what you can do to help animals, so it is nice to raise money for a charity that helps animals around the world."

Dr Bartlett added: "I have never run a marathon before and am excited to run my first one for such a good cause!"

Both Dr Bartlett and Dr O'Neill have fundraising pages online. 

Click here for more...
News Shorts
BSAVA releases new Guide to Procedures

The British Small Animal Veterinary Association (BSAVA) has published a new edition of its Guide to Procedures for Small Animal Practice.

It has added four new procedures; cystostomy tube placement, endotracheal intubation, point-of-care ultrasound and wet-to-dry dressings.

BSAVA says that it is an essential step-by-step guide to diagnostic and therapeutic procedures performed in practice. The textbook includes new images and illustrations, as well as high-definition videos for use prior to procedures.

Nick Bexfield and Julia Riggs, editors of the new edition, said: "We have built upon the success of the previous editions by responding to the feedback received from the BSAVA readership, and hope this new guide helps to further increase the confidence and accuracy with which these procedures are performed."

Print copies are available in the BSAVA store, with a digital version in the BSAVA library.